Studies show that, in general, cancer directed treatments are likely to be ineffective for patients with solid organ tumors who are markedly debilitated by their cancer (i.e., performance status 3 or 4). Exceptions may include patients with functional limitations due to other conditions resulting in a low performance status, or selected patients with specific disease types (e.g., germ cell cancer) or characteristics (e.g., mutations) that suggest a high likelihood of response to therapy. It has also been shown that appropriate symptom control and palliative care can significantly improve quality of life.

Conditions: Cancer, Malignancy, Tumor

Procedures: Chemotherapy, Palliative Care

Sources

• Azzoli CG, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J. Clin. Oncol. Oct 1 2011;29(28):3825-3831. (PubMed)
• Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. Feb 2009;7(2):122-192. (PubMed)
• Engstrom PF, Benson AB, 3rd, Chen YJ, et al. Colon cancer clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. Jul 2005;3(4):468-491. (PubMed)
• Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J. Natl. Compr. Canc. Netw. Jul 2010;8(7):740-801. (PubMed)
• Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J. Clin. Oncol. Feb 20 2011;29(6):755-760. (PubMed)
• Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med. May 26 2011;364(21):2060-2065. (PubMed)
• Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. Aug 19 2010;363(8):733-742. (PubMed)